Foghorn Therapeutics (FHTX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Foghorn Therapeutics (FHTX) is Neutral.

The composite score behind that read is -0.08, weighing +0.27 of bullish evidence against -0.31 bearish.

Foghorn Therapeutics last closed at $2.00, +0.50% on the session.

Against the IVW growth benchmark the position is -0.30% over the forecast window.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 67%.

11 graded predictions for FHTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Foghorn Therapeutics in the 94th percentile on return on equity, where 100 is best.

Foghorn Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $118.18M.

StockMap tracks Foghorn Therapeutics as the 275th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Foghorn Therapeutics ranks 195th of 381 in the group, against a group median of -0.08.